Cargando…

Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study

INTRODUCTION: Treatment continuation is essential for relapse prevention in patients with schizophrenia. The aim of this exploratory study was to compare the time to treatment discontinuation between patients with schizophrenia prescribed brexpiprazole (BRX group) and those prescribed other atypical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hishimoto, Akitoyo, Yasui-Furukori, Norio, Sekine, Daisuke, Matsukawa, Miyuki, Yamada, Sakiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402511/ https://www.ncbi.nlm.nih.gov/pubmed/35904721 http://dx.doi.org/10.1007/s12325-022-02252-9

Ejemplares similares

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2019)

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
por: Yasui‐Furukori, Norio, et al.
Publicado: (2020)

PM399. Attitudes toward antipsychotic long-acting injections among patients with Schizophrenia in Japan.
por: Kudo, Shuhei, et al.
Publicado: (2016)

Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43
por: Fukuyama, Kouji, et al.
Publicado: (2021)

Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist’s Perspective
por: Watanabe, Yoshinori, et al.
Publicado: (2020)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Comparison of predictive equations for resting energy expenditure among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2014)

Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval
por: Okayasu, Hiroaki, et al.
Publicado: (2021)

Body mass index and quality of life among outpatients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2013)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
por: Hashimoto, Kojiro, et al.
Publicado: (2014)

Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2015)

Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
por: Inada, Ken, et al.
Publicado: (2020)

Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers
por: Ishioka, Masamichi, et al.
Publicado: (2015)

Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study
por: Ishigooka, Jun, et al.
Publicado: (2021)

Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
por: Yokoi, Rina, et al.
Publicado: (2023)

Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
por: Ichinose, Mizue, et al.
Publicado: (2021)

Update on the development of lurasidone as a treatment for patients with acute schizophrenia
por: Yasui-Furukori, Norio
Publicado: (2012)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
por: Siwek, Marcin, et al.
Publicado: (2023)

Differences in self‐reported psychotic symptoms between patients with autism spectrum disorder and those with schizophrenia
por: Yamada, Momoka, et al.
Publicado: (2023)

Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?
por: Barman, Rajdip, et al.
Publicado: (2021)

Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics
por: Hori, Hikaru, et al.
Publicado: (2022)

PS108. Characteristics of escitalopram discontinuation syndrome
por: Norio-Furukori, Yasui, et al.
Publicado: (2016)

Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine
por: Tsuda, Yoshiyuki, et al.
Publicado: (2014)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2013)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Comparing the influences of age and disease on the Brief Assessment of Cognition in Schizophrenia in Japanese patients with schizophrenia
por: Kaneda, Ayako, et al.
Publicado: (2013)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Post‐hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long‐term study (Secondary Publication)
por: Ishigooka, Jun, et al.
Publicado: (2020)

Competence to Consent and Its Relationship With Cognitive Function in Patients With Schizophrenia
por: Sugawara, Norio, et al.
Publicado: (2019)

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia
Publicado: (2018)

Projections of psychiatrists’ distribution for patients in Japan: a utilization-based approach
por: Sugawara, Norio, et al.
Publicado: (2021)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
por: Hatano, Masakazu, et al.
Publicado: (2021)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
por: Kirino, Eiji
Publicado: (2017)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka, Michal, et al.
Publicado: (2015)

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
por: Orzelska-Górka, Jolanta, et al.
Publicado: (2022)

Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
por: Moncrieff, Joanna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b0k49uvuqm3t3qpq8amifiara7